AB Science SA

AB Science SA

0.58
EUR
+0.00
(-0.85%)
64.83MMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.06
0.07
0.04
0.05
0.05
0.04
0.04
0.03
0.02
0.02
0.02
0.02
- -
Basic EPS, GAAP
-0.45
-0.49
-0.78
-0.78
-0.75
-0.69
-0.55
-0.34
-0.3
-0.29
-0.24
-0.15
-0.03
- -
Free Cash Flow per Basic Share
-0.4
-0.45
-0.7
-0.95
-0.64
-0.71
-0.38
-0.31
-0.37
-0.38
-0.35
0.01
-0.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
-0.48
-0.49
-0.12
0.26
-0.36
-0.62
-0.43
-0.5
-0.76
-0.41
-0.37
-0.26
-0.31
Tangible Book Value per Share
-0.03
-0.52
-0.54
-0.17
0.22
-0.4
-0.65
-0.46
-0.53
-0.8
-0.44
-0.39
-0.28
-0.32
Basic Weighted Avg Shares
33
33
34
36
36
38
39
44
48
47
50
53
52
70
Sales/Revenue/Turnover
2
2
2
2
2
2
2
2
2
1
1
1
1
- -
Operating Margin (%)
-712.42
-724.3
-1,136.78
-2,003.05
-1,633.35
-1,701.53
-1,112.29
-931.71
-859.24
-1,663.67
-1,384.43
-567.44
54.43
- -
Depreciation Expense
1
- -
- -
1
- -
1
1
1
2
- -
2
1
- -
- -
Net Income, GAAP
-15
-16
-27
-28
-27
-26
-22
-15
-14
-14
-12
-8
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-755.87
-767.6
-1,169.7
-1,836.6
-1,559.63
-1,532.1
-1,384.28
-950.41
-900
-1,421.19
-1,235.57
-730.5
-132.62
- -
Working Capital
29
16
13
16
30
2
-5
4
1
-2
1
-6
-1
-2
LT Debt
22
23
22
- -
- -
- -
2
2
8
19
17
15
19
19
Total Equity
- -
-16
-17
-5
11
-15
-27
-20
-23
-36
-21
-24
-17
-22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-557.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
ST Debt
2
4
1
LT Borrowings
16
14
18
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
65
73
Market Capitalization
58
56
65

Working Capital

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
Total Current Assets
14
15
13
Cash, Cash Equivalents & STI
9
8
9
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
1
Total Current Liabilities
18
20
15
Payables & Accruals
- -
- -
- -
ST Debt
2
4
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-57.13%
3.36%
-27.6%
Free Cash Flow
-143.7%
-282.52%
-1,335.41%
Net Income, GAAP
-18.62%
-27.3%
-80.12%
Sales/Revenue/Turnover
-4.53%
-3.52%
9.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.15
2025
- -
- -
-0.03
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Stéphane Ledermann
Full Time Employees
36
Sector
Health technology
Industry
Pharmaceuticals: other
Address
3, Avenue George V Paris IF France 75008
IPO Date
Apr 27, 2010
Business
AB Science S.A. AB Science S.A. (AB.PA) is a French clinical-stage pharmaceutical company that researches, develops, and commercializes protein kinase inhibitors and targeted therapies for diseases with high unmet medical needs in humans and veterinary medicine; its lead product, masitinib, a highly selective tyrosine kinase inhibitor, targets oncology, inflammatory diseases such as severe asthma and ALS, neurological disorders including multiple sclerosis, and viral diseases, while registered for veterinary use in mast cell tumors; the company also advances AB8939, a new generation microtubule destabilizer, primarily in acute myeloid leukemia with ongoing phase 1 expansion studies in combination with venetoclax. Founded in 2001 and headquartered at 3 Avenue George V in Paris, France, AB Science S.A. operates globally through clinical trials across Europe and North America, supported by a U.S. subsidiary in New Jersey, with nearly 40 employees focused on R&D and listed on Euronext Paris since 2010. In recent developments, the company completed multiple private placements totaling over EUR 9 million between May and October 2025, including EUR 2.8 million in October to fund AB8939 phase 1 completion and expansion in AML, alongside EUR 1.8 million in May, EUR 1.925 million in July, and EUR 2.55 million in August, securing financing beyond 12 months; it received regulatory approvals in 2025 from European countries for AB8939 phase I/II confirmatory studies and masitinib ALS phase 3 initiation, while extending Masivet shelf-life to four years via EMA approval.